Endpoints News – Biotech and pharma business news, with a focus …
Biotech and pharma business news, with a focus on the science, people and money that drive the industry.
Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Novartis buys Kate Therapeutics in $1.1B deal, eyes more bolt-on …
Nov 21, 2024 · Novartis is acquiring Kate Therapeutics for $1.1 billion, focusing on gene therapy and neuroscience. CEO Vas Narasimhan and CFO Harry Kirsch indicate future M&A deals will likely stay under $3 ...
Speakers: Endpoints at #JPM25 - events.endpts.com
Jan 13, 2025 · Managing Director, Global Head of Shareholder Activism & Corporate Defense. Morgan Stanley. Stephen J. Ubl
AbbVie makes another small I&I acquisition, buying Nimble for …
Dec 13, 2024 · In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune startup.
GSK leaves biotech trade group BIO - endpts.com
Nov 8, 2024 · GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group. “ At this time, we …
Agenda: Endpoints at #JPM25 - events.endpts.com
Jan 13, 2025 · How a new Washington affects biopharma: In conversation with Scott Gottlieb . Investor, policy expert and former FDA Commissioner Scott Gottlieb will share his insights on how the Trump administration’s new priorities will affect the biopharma industry, in what could be a turbulent time of policy and political changes.
Exclusive: Blood stem cell therapy maker Garuda gets new CEO, …
Nov 1, 2024 · Garuda Therapeutics has replaced its top leader and reeled in about $47 million to continue funding its blood stem cell therapy work, Endpoints News has …
Big dreams dominate among next-gen biotech players
Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a biotech. Here’s John Carroll’s top picks for the next-gen players of 2022 most likely to make their mark — or go down fighting for a landmark change.
Endpoints at #ASH24
Dec 10, 2024 · In conversation with Crystal Mackall . Crystal Mackall is a leading expert on immuno-oncology and a cell therapy pioneer. Join us for an in-depth discussion on her research and her efforts to expand access to pediatric cell & gene therapies — including through a new non-profit aiming to create new pathways for commercialization